A Phase 4 interventional study of Botulinum toxin in Tears; Excess and Eyelid Spasm, sponsored by University of Miami. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-05.
Sponsored by University of Miami · Phase 4, Interventional, and Treatment
Among 60 studies in Lacerations with a site in United States — 12 open to participants now, 14 under way, 1 of them phase 3. Lacerations · United States.
Among the 60 studies in Lacerations with a site in United States, this one is the 46th largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2022, is one of 10 in phase 4, and was the 48th registered.
174 studies on the registry are indexed under Lacerations; 43 are open to participants now.
Browse Lacerations studies →12 of the 60 studies in Lacerations with a site in United States are open now. Recruiting first, the newest first:
Ohio State University · Sites in United States
Stanford University · Sites in United States
University of California, Berkeley · Sites in United States
Florida Atlantic University · Sites in United States
Brett Lewellyn · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Lacerations studies recruiting now, 15 (56%) set no upper age limit and 10 (37%) stop at 75 or younger; 6 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 2 · Phase 4 10
First in 2000; this study’s year is marked. 3 started in 2022.
This study's enrollment of 2 is below the median of 65 across 128 interventional studies indexed under Lacerations.
Median enrollment 52 across the 52 interventional studies, 50 across the 7 observational. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 60 have an industry lead sponsor. The 10 most frequent:
University of Miami is the lead sponsor of 840 studies on the registry; 164 are open to participants now.
Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.
University of Miami has 1 study filed under Lacerations — fewer than ten, so there is no comparison to draw.
6 of the studies in Lacerations with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06910241Phase 3Florida Atlantic UniversityLidocaine Versus Diphenhydramine to Achieve Local Anesthesia for Laceration Repairs | 2027-06-30 |
| NCT07606625University of California, BerkeleyOcular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment | 2026-12-31 |
| NCT07068880Brett LewellynClinical Analysis of a Novel Flexor Tendon Repair Technique | 2027-01 |
| NCT07632183Edward Via Virginia College of Osteopathic MedicineWill a Hands on Technique Applied to the Face Increase the Tear Production in Participants | 2027-06 |
| NCT07688967Arthroresearch LLCMeasuring Knee Laxity and Pivot Shift in ACL-Deficient Patients | 2027-07 |
Among the 60 studies in Lacerations with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to test if Topical (applied to the surface of the eye) Botulinum Toxin temporarily lowers the upper eyelid and makes the eyelid appear less open and thereby affects the eye surface and decreases reflexive tearing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women who are breast-feeding
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The left eye of each participant will receive botulinum toxin eye drops and will remain in this group for up to 40 minutes.
Drug: Botulinum toxin
15 units of botulinum toxin administered one time to the eye via eye drops
Also known as: BOTOX
Change in Palpebral Fissure Height
Palpebral fissure on Day 3 minus palpebral fissure at baseline. Palpebral fissure is the area between the upper and lower eyelid margins. Palpebral fissure height on eyes is measured in primary gaze position with a clear ruler held in a central vertical position between the upper and lower eyelid margin.
Time frame: baseline and Day 3
Corneal Staining Density
Scoring of the ocular surface will be done by fluorescein staining and evaluating with a slit lamp and grading scale: 0-3 0 (no punctate staining) 1. (sparse density) 2. (moderate density) 3. (high density and overlapping lesions).
Time frame: Baseline
Corneal Staining Density
Scoring of the ocular surface will be done by fluorescein staining and evaluating with a slit lamp and grading scale: 0-3 0 (no punctate staining) 1. (sparse density) 2. (moderate density) 3. (high density and overlapping lesions).
Time frame: Day 3
Change in Tearing
Change in tearing will be calculated as tearing on Day 3 minus tearing at baseline. Tearing will be assessed using the Schirmer test with anesthesia. Schirmer strip is inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters is recorded after 5 minutes. The result can range from a minimum of 0 mm (no tearing) to a maximum of 35 mm (maximum tearing).
Time frame: baseline and Day 3
| Milestone | Botulinum Toxin Group |
|---|---|
| Started | 2 |
| Completed | 0 |
| Not completed | 2 |
| Withdrew: Lost to follow-up | 2 |
Palpebral fissure on Day 3 minus palpebral fissure at baseline. Palpebral fissure is the area between the upper and lower eyelid margins. Palpebral fissure height on eyes is measured in primary gaze position with a clear ruler held in a central vertical position between the upper and lower eyelid margin.
| mm | Botulinum Toxin Group |
|---|---|
| Change in Palpebral Fissure Height | -0.5 ± 0.69 |
Scoring of the ocular surface will be done by fluorescein staining and evaluating with a slit lamp and grading scale: 0-3 0 (no punctate staining) 1. (sparse density) 2. (moderate density) 3. (high density and overlapping lesions).
| score on a scale | Botulinum Toxin Group |
|---|---|
| Corneal Staining Density | 2 ± 0 |
Scoring of the ocular surface will be done by fluorescein staining and evaluating with a slit lamp and grading scale: 0-3 0 (no punctate staining) 1. (sparse density) 2. (moderate density) 3. (high density and overlapping lesions).
| score on a scale | Botulinum Toxin Group |
|---|---|
| Corneal Staining Density | 2 ± 0 |
Change in tearing will be calculated as tearing on Day 3 minus tearing at baseline. Tearing will be assessed using the Schirmer test with anesthesia. Schirmer strip is inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding touching the cornea, and the length of wetting strips in millimeters is recorded after 5 minutes. The result can range from a minimum of 0 mm (no tearing) to a maximum of 35 mm (maximum tearing).
| mm | Botulinum Toxin Group |
|---|---|
| Change in Tearing | 3 ± 5.54 |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Botulinum Toxin Group | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Age, Categorical(Participants) | Botulinum Toxin Group |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 2 |
| >=65 years | 0 |
| Age, Continuous(years) | Botulinum Toxin Group |
|---|---|
| Mean | 57 ± 4.2 |
| Sex: Female, Male(Participants) | Botulinum Toxin Group |
|---|---|
| Female | 2 |
| Male | 0 |
| Race (NIH/OMB)(Participants) | Botulinum Toxin Group |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 2 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Palpebral fissure(mm) | Botulinum Toxin Group |
|---|---|
| Mean | 11.75 ± 0.42 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2022 to primary completion in Jul 2024, 19 months.
Results were first posted in Dec 2024, 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum Toxins